


PRODUCT INFORMATION



Tideglusib

Item No. 16727

CAS Registry No.: 865854-05-3
Formal Name: 2-(1-naphthalenyl)-4-(phenylmethyl)-1,2,4-thiadiazolidine-3,5-dione
Synonym: NP031112
MF: C₁₉H₁₄N₂O₂S
FW: 334.4
Purity: ≥98%
UV/Vis.: λ_{max}: 225, 285 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tideglusib is supplied as a crystalline solid. A stock solution may be made by dissolving the tideglusib in the solvent of choice, which should be purged with an inert gas. Tideglusib is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of tideglusib in these solvents is approximately 1 mg/ml.

Tideglusib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, tideglusib should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Tideglusib has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Tideglusib is a thiadiazolidinone that prevents inflammation and neurodegeneration when injected into rat hippocampus concurrently with kainic acid, a compound that causes excitotoxicity.¹ Tideglusib-induced neuroprotection, in this model, is attenuated by the PPAR γ antagonist GW9662 (Item No. 70785).¹ Interestingly, tideglusib also irreversibly inhibits glycogen synthase kinase-3 β (GSK3 β) with an IC₅₀ value of 5 nM when used with a one hour preincubation, increasing to 0.1-1 μ M without preincubation.^{2,3} Several GSK3 inhibitors, including tideglusib, promote hippocampal neurogenesis both *in vitro* and *in vivo*, suggesting suitability in Alzheimer's therapy.^{3,4}

References

1. Luna-Medina, R., Cortes-Canteli, M., Sanchez-Galiano, S., *et al.* NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: Potential therapeutic role in brain disorders. *J. Neurosci.* **27(21)**, 5766-5776 (2007).
2. Domínguez, J.M., Fuertes, A., Orozco, L., *et al.* Evidence for irreversible inhibition of glycogen synthase kinase-3 β by tideglusib. *J. Biol. Chem.* **287(2)**, 893-904 (2012).
3. Morales-García, J.A., Luna-Medina, R., Alonso-Gil, S., *et al.* Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis *in vitro* and *in vivo*. *ACS Chem. Neurosci.* **3(11)**, 963-971 (2012).
4. Martínez, A., Gil, C., and Pérez, D.I. Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment. *Int. J. Alzheimers Dis.* **280502** (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/01/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM